Want to see GB:HEMO full AI Analyst Report?
Top Page
HemoGenyx Pharmaceuticals Plc
(LSE:HEMO)
Select Model
Select Model
Rating:49Neutral
Price Target:
616.00 p
▲(10.79% Upside)
Action:Reiterated
Date:10/06/26
The score is held back primarily by weak financial performance: no revenue, persistent losses, ongoing cash burn, and a pressured balance sheet with debt exceeding a shrinking equity base. Technicals are mixed—near-term strength but overbought signals and a negative MACD—while valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Debt Reduction
Lower total debt provides some improvement in financial flexibility, even though leverage remains material. If maintained, continued debt reduction could reduce financing pressure and preserve more resources for research and development over the next several quarters.
Negative Factors
Pre-Revenue Profile
The absence of reported revenue means the company has not yet demonstrated commercial traction or an internally generated funding base. Until products, partnerships, or other programs produce income, continued development will depend heavily on external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt Reduction
Lower total debt provides some improvement in financial flexibility, even though leverage remains material. If maintained, continued debt reduction could reduce financing pressure and preserve more resources for research and development over the next several quarters.
Read all positive factors
HemoGenyx Pharmaceuticals Plc (HEMO) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£47.59M
Dividend YieldN/A
Average Volume (3M)28.58K
Price to Earnings (P/E)―
Beta (1Y)-0.25
Revenue GrowthN/A
EPS Growth18.57%
CountryUK
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.81
Shares Outstanding6,896,786
10 Day Avg. Volume24,995
30 Day Avg. Volume28,580
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)21.26
Price to Sales (P/S)0.00
P/FCF Ratio-7.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HemoGenyx Pharmaceuticals Plc Business Overview & Revenue Model
Company Description
Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel soluti...
How the Company Makes Money
Publicly available information in the provided context is insufficient to describe HemoGenyx Pharmaceuticals Plc’s specific, current revenue model and key revenue streams in a factual, detailed way (e.g., whether it earns revenue from product sale...
HemoGenyx Pharmaceuticals Plc Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
26
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -521.15K | -588.75K | -639.28K | -645.68K | -2.60M | -283.65K |
| EBITDA | -9.05M | -4.07M | -4.71M | -5.73M | -3.42M | -2.39M |
| Net Income | -11.31M | -9.76M | -5.62M | -6.69M | -3.98M | -5.10M |
Balance Sheet | ||||||
| Total Assets | 6.87M | 4.18M | 4.21M | 6.11M | 7.09M | 8.52M |
| Cash, Cash Equivalents and Short-Term Investments | 4.58M | 1.59M | 159.26K | 1.25M | 2.53M | 6.84M |
| Total Debt | 1.85M | 2.00M | 2.62M | 2.95M | 3.42M | 10.15K |
| Total Liabilities | 2.60M | 3.03M | 3.36M | 3.32M | 3.85M | 352.84K |
| Stockholders Equity | 4.33M | 1.20M | 897.51K | 2.82M | 3.28M | 8.19M |
Cash Flow | ||||||
| Free Cash Flow | -1.32M | -3.45M | -4.13M | -6.22M | -3.34M | -3.45M |
| Operating Cash Flow | -1.32M | -3.45M | -4.12M | -6.11M | -2.91M | -2.63M |
| Investing Cash Flow | -271.93K | -6.80K | -24.90K | -31.94K | -420.25K | -938.95K |
| Financing Cash Flow | 7.92M | 4.89M | 3.08M | 4.45M | -110.14K | 8.78M |
HemoGenyx Pharmaceuticals Plc Technical Analysis
Neutral
556.00
Price Trends
558.46
Positive
655.66
Negative
748.14
Negative
Market Momentum
24.11
Negative
59.68
Neutral
63.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:HEMO, the sentiment is Neutral. The current price of 556 is above the 20-day moving average (MA) of 503.85, below the 50-day MA of 558.46, and below the 200-day MA of 748.14, indicating a neutral trend. The MACD of 24.11 indicates Negative momentum. The RSI at 59.68 is Neutral, neither overbought nor oversold. The STOCH value of 63.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:HEMO.
HemoGenyx Pharmaceuticals Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £54.97M | -8.85 | -71.28% | ― | ― | 31.58% | |
49 Neutral | £47.59M | -3.42 | -409.57% | ― | ― | 18.57% | |
49 Neutral | £39.58M | -3.39 | -35.13% | 3.48% | -24.24% | -329.49% | |
47 Neutral | £32.70M | 145.00 | 3.75% | ― | ― | ― | |
46 Neutral | £11.27M | -3.25 | -135.35% | ― | 13.42% | 65.63% | |
44 Neutral | £21.34M | -2.63 | -559.87% | 17.86% | ― | 5.62% |
* Healthcare Sector Average
GB:HEMO
HemoGenyx Pharmaceuticals Plc
619.00
-616.00
-49.88%
GB:IMM
ImmuPharma
3.29
-8.42
-71.92%
GB:HVO
Open Orphan Plc
6.10
-0.35
-5.43%
GB:POLB
Poolbeg Pharma Ltd.
6.90
3.35
94.37%
GB:AREC
Arecor Therapeutics PLC
72.50
-5.00
-6.45%
GB:APTA
Aptamer Group Plc
0.33
-0.78
-70.45%
HemoGenyx Pharmaceuticals Plc Corporate Events
Regulatory Filings and Compliance
Hemogenyx clarifies total voting rights and share capital
Neutral
Sep 30, 2026
Hemogenyx Pharmaceuticals plc has confirmed that its total issued share capital as of 30 September 2026 stands at 6,896,786 ordinary shares of 1p each, with no shares held in treasury. This means the company currently has 6,896,786 voting rights i...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Hemogenyx Advances AML CAR-T Trial and Sets Up Early European Commercial Pathways
Positive
Sep 28, 2026
Hemogenyx Pharmaceuticals reported interim results for the six months to 30 June 2026, highlighting continued progress of its HG-CT-1 CAR-T therapy for relapsed/refractory acute myeloid leukaemia. The company’s second annual FDA IND report s...
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Hemogenyx Raises £291,665 Through Warrant Exercises Ahead of LSE Admission
Positive
Sep 3, 2026
Hemogenyx Pharmaceuticals plc has received notices to exercise warrants over 96,825 new ordinary shares, at prices between 180p and 350p, raising £291,665 in fresh capital. The new shares will rank pari passu with existing stock and are expec...
Business Operations and Strategy
Hemogenyx Expands FLT3 CAR-T Effort With Vilnius Hospital Collaboration
Positive
Jul 29, 2026
Hemogenyx Pharmaceuticals has signed a Letter of Intent with the National Cancer Centre at Vilnius University Hospital Santaros Klinikos to collaborate on FLT3-positive acute myeloid leukemia and myelodysplastic syndromes. The partnership combines...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.